desloratadine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
histamine-H1 receptor antagonists, tricyclic compounds 814 100643-71-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • SCH-34117
  • SCH 34117
  • desloratadine
  • azomyr
  • delopedil
  • descarboethoxyloratadine
  • descarboethoxyloratidine
  • neoclarityn
major metabolite of loratadine
  • Molecular weight: 310.83
  • Formula: C19H19ClN2
  • CLOGP: 3.83
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 24.92
  • ALOGS: -4.90
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.23 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 2001 FDA MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 221.82 37.06 52 524 8344 2349165
Drug reaction with eosinophilia and systemic symptoms 108.24 37.06 27 549 5491 2352018
Urticaria 106.06 37.06 37 539 24224 2333285
Allergy test positive 84.49 37.06 11 565 45 2357464
Tachycardia 71.38 37.06 25 551 16384 2341125
Cerebral thrombosis 69.95 37.06 12 564 378 2357131
Tooth injury 62.26 37.06 10 566 208 2357301
Drug hypersensitivity 60.77 37.06 30 546 46613 2310896
Terminal dribbling 53.39 37.06 6 570 3 2357506
Eosinophilia 45.67 37.06 12 564 2958 2354551
Intentional overdose 44.38 37.06 16 560 11305 2346204
Confusional state 41.83 37.06 19 557 24325 2333184
Depression 39.20 37.06 19 557 28113 2329396
Dyspepsia 38.90 37.06 14 562 9830 2347679
Electrocardiogram QT prolonged 38.10 37.06 13 563 7801 2349708
Suicidal ideation 37.27 37.06 14 562 11073 2346436
Pancoast's syndrome 37.21 37.06 4 572 0 2357509

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Somnolence 58.96 40.78 23 403 16716 1729639
Electrocardiogram QT prolonged 52.51 40.78 16 410 5529 1740826
Aggression 50.46 40.78 17 409 8098 1738257
Vasoplegia syndrome 47.03 40.78 8 418 194 1746161
Myoglobin blood increased 46.47 40.78 9 417 457 1745898
Eosinophilia 45.77 40.78 13 413 3514 1742841
Pruritus 45.31 40.78 21 405 23201 1723154

Pharmacologic Action:

SourceCodeDescription
ATC R06AX27 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Other antihistamines for systemic use
FDA MoA N0000000190 Histamine H1 Receptor Antagonists
FDA EPC N0000175587 Histamine-1 Receptor Antagonist
CHEBI has role CHEBI:37955 H1-receptor antagonist
CHEBI has role CHEBI:50857 anti-allergic agent
CHEBI has role CHEBI:48873 cholinergic antagonist
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D039563 Histamine H1 Antagonists, Non-Sedating
MeSH PA D018377 Neurotransmitter Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Vasomotor rhinitis indication 8229003 DOID:4730
Allergic urticaria indication 40178009 DOID:10612
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Sneezing indication 76067001
Common cold indication 82272006 DOID:10459
Chronic idiopathic urticaria indication 302162004
Seasonal allergic rhinitis indication 367498001
Allergic conjunctivitis indication 473460002 DOID:11204
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Hypertensive urgency contraindication 443482000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.92 Basic
pKa2 2.48 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
2.5MG CLARINEX MERCK SHARP DOHME N021312 July 14, 2005 RX TABLET, ORALLY DISINTEGRATING ORAL 7618649 Dec. 19, 2020 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
5MG CLARINEX MERCK SHARP DOHME N021312 June 26, 2002 RX TABLET, ORALLY DISINTEGRATING ORAL 7618649 Dec. 19, 2020 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
2.5MG CLARINEX-D 12 HOUR MERCK SHARP DOHME N021313 Feb. 1, 2006 RX TABLET, EXTENDED RELEASE ORAL 7618649 Dec. 19, 2020 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
2.5MG CLARINEX-D 12 HOUR MERCK SHARP DOHME N021313 Feb. 1, 2006 RX TABLET, EXTENDED RELEASE ORAL 8187630 Dec. 19, 2020 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
5MG CLARINEX D 24 HOUR MERCK SHARP DOHME N021605 March 3, 2005 RX TABLET, EXTENDED RELEASE ORAL 7618649 Dec. 19, 2020 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
2.5MG CLARINEX-D 12 HOUR MERCK SHARP DOHME N021313 Feb. 1, 2006 RX TABLET, EXTENDED RELEASE ORAL 6709676 Feb. 18, 2021 ALLERGIC RHINITIS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 9.40 WOMBAT-PK CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.91 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.96 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 8.02 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 7.55 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.80 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.00 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 6.01 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.19 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.97 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.51 DRUG MATRIX
Multidrug resistance protein 1 Transporter IC50 4.37 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR Ki 7.30 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR Ki 7.70 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR Ki 7.49 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 7.60 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 7.74 WOMBAT-PK
Alpha-1B adrenergic receptor GPCR Ki 5.70 DRUG MATRIX

External reference:

IDSource
4021292 VUID
N0000148729 NUI
C0908935 UMLSCUI
D03693 KEGG_DRUG
134506008 SNOMEDCT_US
d04785 MMSL
16243 MMSL
275635 RXNORM
4021292 VANDF
396015008 SNOMEDCT_US
009081 NDDF
83662 MMSL
CHEMBL1172 ChEMBL_ID
DB00967 DRUGBANK_ID
FVF865388R UNII
7817 INN_ID
CHEBI:291342 CHEBI
7157 IUPHAR_LIGAND_ID
124087 PUBCHEM_CID
C121345 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 0085-1264 TABLET, FILM COATED 5 mg ORAL NDA 19 sections
CLARINEX-D 12 HOUR HUMAN PRESCRIPTION DRUG LABEL 2 0085-1322 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 19 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 0085-1334 SOLUTION 0.50 mg ORAL NDA 19 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 21695-815 TABLET, FILM COATED 5 mg ORAL NDA 12 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 42291-240 TABLET 5 mg ORAL ANDA 17 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 50090-3975 TABLET 5 mg ORAL ANDA 20 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 50090-4794 TABLET, FILM COATED 5 mg ORAL ANDA 18 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 54868-4624 TABLET, FILM COATED 5 mg ORAL NDA 11 sections
Clarinex-D 12 Hour HUMAN PRESCRIPTION DRUG LABEL 2 54868-5708 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 19 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 55111-360 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 18 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 55111-551 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 18 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 62250-619 TABLET 5 mg ORAL ANDA 17 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 62756-523 TABLET, FILM COATED 5 mg ORAL ANDA 18 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 63629-5270 TABLET 5 mg ORAL ANDA 19 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 65729-384 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL Export only 1 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 65729-408 TABLET, ORALLY DISINTEGRATING 5 mg ORAL Export only 1 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 68180-153 TABLET, FILM COATED 5 mg ORAL ANDA 18 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 69543-107 TABLET 5 mg ORAL ANDA 19 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 71335-1000 TABLET, FILM COATED 5 mg ORAL ANDA 18 sections